Zanubrutinib

證據等級: L5

預測適應症: 6 個

Zanubrutinib: From B-Cell Malignancies to Myeloid Leukemia

One-Sentence Summary

Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor whose established evidence base (per the literature in this pack) centers on B-cell malignancies such as CLL/SLL and Waldenström macroglobulinemia. The TxGNN model predicts it may be effective for Myeloid Leukemia, with a prediction score of 99.65%, but none of the cited clinical trials or publications directly study zanubrutinib in myeloid leukemia — the trials involve different investigational drugs, and the literature supports only its known lymphoid-malignancy indications.

Quick Overview

Item	Content
Original Indication	Not formally recorded in this pack (no BfArM license data; literature indicates zanubrutinib is an established BTK-inhibitor therapy for CLL/SLL and other B-cell malignancies)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.65%
Evidence Level	L5 (model prediction only — cited trials involve unrelated drugs; cited literature does not address myeloid leukemia)
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data from DrugBank is currently unavailable (blocking data gap, DG002). Based on the information available in this evidence pack, zanubrutinib is a next-generation, highly selective BTK inhibitor that blocks B-cell receptor signaling — a pathway central to B-cell malignancies. Its clinical evidence (SEQUOIA, ALPINE and related studies) is concentrated almost entirely in CLL/SLL and Waldenström macroglobulinemia.

Myeloid leukemia arises from a different hematopoietic lineage than CLL/SLL, and BTK is not established as a key driver in myeloid malignancies the way it is in B-cell lymphoid disease. The two clinical trials retrieved under this predicted indication (NCT04477291, NCT05665530) do not actually test zanubrutinib for myeloid leukemia — they involve different investigational agents (luxeptinib/CG-806 and PRT2527) that happen to co-occur in the same trial registry search, or use zanubrutinib only as a combination comparator in unrelated hematologic malignancies. Taken together, this prediction most likely reflects an over-generalization of the TxGNN embedding for the broad "leukemia" disease category, rather than a mechanistically grounded hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04477291	Phase 1	Terminated	45	Tests luxeptinib (CG-806), not zanubrutinib, in relapsed/refractory AML/MDS; trial terminated — not usable as supporting evidence
NCT05665530	Phase 1	Completed	86	Tests PRT2527 (CDK9 inhibitor) monotherapy and in combination with zanubrutinib or venetoclax in relapsed/refractory hematologic malignancies; zanubrutinib is a combination arm comparator, not the study drug for myeloid leukemia specifically

Note: Neither trial provides direct evidence for zanubrutinib monotherapy efficacy in myeloid leukemia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39647999	2025	RCT	J Clin Oncol	SEQUOIA 5-year follow-up: zanubrutinib vs bendamustine+rituximab in treatment-naïve CLL/SLL
40334067	2025	Cohort	Blood Advances	Zanubrutinib well tolerated/effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib
40829104	2026	Review	Blood Advances	Pooled analysis of zanubrutinib in del(17p)/TP53-mutated CLL/SLL across SEQUOIA and ALPINE
36400069	2023	Cohort	Lancet Haematol	Phase 2 single-arm study of zanubrutinib in BTK-inhibitor-intolerant B-cell malignancies
34959482	2021	Review	Pharmaceutics	TKI-era review of CML and CLL, general context on tyrosine kinase pathways
36402930	2023	Review	Leukemia	BTK inhibitors, including zanubrutinib, in Waldenström macroglobulinemia
36325357	2022	Case Report	Front Immunol	Case report of coexisting WM and B-ALL, unrelated to zanubrutinib treatment outcomes
37150651	2023	Review	Clin Lymphoma Myeloma Leuk	HBV reactivation risk in patients receiving BTK inhibitors, including zanubrutinib
38288815	2024	Review	Anticancer Agents Med Chem	General synthetic-chemistry review of FDA-approved anticancer drugs (2018–2021), not disease-specific

Important: None of the above publications specifically study zanubrutinib in myeloid leukemia. They represent the drug's established evidence base for B-cell malignancies (CLL/SLL, Waldenström) plus general safety/chemistry reviews. No direct literature evidence for the predicted myeloid leukemia indication was found.

Germany Market Information

Zanubrutinib is currently not marketed in Germany (0 BfArM authorizations on record in this pack).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (BTK inhibitor; oral small-molecule kinase inhibitor, not conventional cytotoxic chemotherapy)
Myelosuppression Risk	Please refer to the package insert warnings and precautions (no quantitative toxicity data in this pack)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential; hepatitis B serology/viral load — HBV reactivation has been reported with BTK inhibitors including zanubrutinib (PMID 37150651)
Handling Protection	Please refer to the package insert and institutional hazardous drug handling policy

Safety Considerations

Please refer to the package insert for safety information (key warnings, contraindications, and drug-drug interaction data are all currently unavailable in this pack — DG001, blocking).

Signal from literature (not formal safety labeling): BTK inhibitors as a class, including zanubrutinib, have been associated with hepatitis B virus reactivation (PMID 37150651); HBV screening should be considered before initiating therapy pending confirmation from official labeling.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but the supporting evidence is not substantive — the two retrieved clinical trials involve different investigational drugs, and all retrieved literature supports zanubrutinib's established B-cell malignancy indications rather than myeloid leukemia. Combined with a blocking data gap on approved-label warnings/contraindications (DG001) and the fact that the drug is not currently marketed in Germany, this candidate cannot advance past S0.

To proceed, the following is needed:

Resolve DG001: BfArM/manufacturer label warnings and contraindications, required before any S1 safety screening
Resolve DG002: Confirmed mechanism-of-action data from DrugBank
Any dedicated preclinical, mechanistic, or clinical evidence linking BTK signaling to myeloid leukemia pathogenesis (currently absent)
Correction of the clinical-trial matching pipeline, since both retrieved trials are drug-mismatched and should not have been attributed to this candidate

Additional note: Ranks 2–6 (vertebral anomalies syndrome, ganglioneuroblastoma, retroperitoneal neoplasm, Ewing sarcoma, neuroblastoma) are all Evidence Level L5 with zero or near-zero supporting trials/literature and no plausible mechanistic link to BTK inhibition. These should be deprioritized unless new external evidence emerges.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.